Off-the-Shelf CAR T Shows Early Signal in Progressive Multiple Sclerosis
Phase I data show B-cell depletion and mostly stable or improved disability scores, but the uncontrolled study remains small and follow-up is limited
False
Phase I data show B-cell depletion and mostly stable or improved disability scores, but the uncontrolled study remains small and follow-up is limited
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
November 2, 2026
2 min read
Phase I data show B-cell depletion and mostly stable or improved disability scores, but the uncontrolled study remains small and follow-up is limited
November 2, 2026
5 min read
Early characterization and manufacturing planning can help developers choose the right formulation strategy for complex oral therapies
October 29, 2026
9 min read
AmacaThera Co-Founder and CEO Mike Cooke reflects on the long road from academic discovery to a potential new treatment for post-operative pain
October 27, 2026
2 min read
Global deployment of Veeva Vault CRM aims to help Amgen uncover treatment barriers and accelerate the delivery of new therapies
False
Affiliations:
Specialties:
Areas of Expertise: